HPV Rapid Test Device (Urine)

Human Papillomavirus (HPV) is a group of viruses, some of which are considered high-risk because persistent infection may contribute to cervical cancer and other HPV-related cancers. In women’s health, HPV testing is important because high-risk HPV types are linked with cervical precancer and cervical cancer. The HPV Rapid Test Device can support early screening awareness, especially in reproductive health and cervical health programs.

The HPV Rapid Test Device (Urine) is intended for the detection or screening support of HPV-related markers in urine samples, depending on the product’s validated test principle. It is designed as a rapid diagnostic support tool, not as a final standalone diagnosis.

Applications

• Women’s health screening programs
• Fertility and reproductive health clinics
• Gynecology departments
• STI screening centers
• Diagnostic laboratories
• Public health outreach programs
• International diagnostic distribution channels

The HPV Rapid Test Device by LARKSOIS Pharma is listed with the colloidal gold method. Colloidal gold rapid tests commonly use labeled particles to create visible test results when the target marker is present in the sample. This type of rapid test format is widely used in point-of-care diagnostics because it is simple, fast, and easy to interpret.

Benefits

• Fast visual result format
• Simple urine sample workflow
• No complex laboratory instrument required
• Suitable for clinic and screening environments
• Easy-to-handle cassette/device format
• Practical for international supply
• Useful for high-volume screening support

The HPV Rapid Test Device uses urine as the specimen. Urine collection is non-invasive, convenient, and more acceptable for many users compared with cervical sampling. This makes the HPV Rapid Test Device (Urine) useful in screening campaigns, fertility centers, gynecology clinics, and locations where patient comfort and easy collection are important.

Guidance

• Collect urine in a clean and dry container
• Use the sample according to the product insert
• Avoid testing during menstruation if the IFU recommends avoiding it
• Do not use contaminated or improperly stored samples
• Read results only within the stated time window
• Do not reuse the test device

Note

The final LARKSOIS Pharma content should describe the exact test principle, sample requirements, result time, and limitations from the official product IFU.

• HPV screening is important because persistent high-risk HPV infection can lead to cervical cell changes over time.
• The HPV Rapid Test Device (Urine) may support wider screening access by offering a urine-based sample option. Research suggests urine HPV testing can be promising, but performance depends on sample collection method, assay type, target HPV types, and clinical setting.
• For this reason, the HPV Rapid Test Device by LARKSOIS Pharma should be presented as a screening-support product. Positive or uncertain results should be followed by professional medical evaluation and confirmatory testing according to local guidelines.

Steps

• Bring the test device and urine sample to the recommended testing condition
• Open the sealed pouch only when ready to test
• Collect urine in a clean and dry container
• Prepare the urine sample according to the product insert
• Apply the required sample to the test device according to instructions
• Wait for the control and test indicators to appear
• Read the result within the approved time window

Note

The exact testing procedure must follow the official LARKSOIS Pharma product insert or IFU supplied with the HPV Rapid Test Device.

Positive

A positive result suggests that the target HPV-related marker has been detected in the urine sample. This does not automatically mean cancer is present. It indicates that further clinical evaluation may be required.

Negative

A negative result suggests that the target marker was not detected or was below the detection level of the test. A negative result does not fully exclude HPV infection if the sample was collected too early, incorrectly, or if the viral level was low.

Invalid

If the control indicator does not appear, the test is invalid. The test should be repeated with a new HPV Rapid Test Device and a fresh urine sample.

The HPV Rapid Test Device (Urine) is a screening-support test. It should not replace regular cervical cancer screening or physician evaluation where those services are available.

Instructions

• Use only for in vitro diagnostic purposes
• Follow the official product insert carefully
• Do not use expired or damaged test devices
• Do not reuse the device
• Avoid contaminated samples
• Interpret results within the recommended time
• Confirm positive results with appropriate clinical evaluation

Note

The HPV Rapid Test Device by LARKSOIS Pharma should be supplied with clear instructions, storage guidance, result interpretation details, and performance information.

Instructions

• Store in a clean and dry place
• Keep away from direct sunlight
• Do not freeze unless stated on the label
• Keep sealed until use
• Use before the expiry date
• Do not use if the pouch is damaged
• Follow the storage temperature printed on the pack

Instructions

• For in vitro diagnostic screening support only
• Use urine specimen only as validated by the product insert
• Do not use as a final cancer diagnosis
• Do not replace regular cervical screening or medical evaluation where required
• Positive or uncertain results should be reviewed by a healthcare professional
• Use only within the approved reading time
• Follow local HPV screening and women’s health guidelines

LARKSOIS Pharma provides diagnostic products for international healthcare markets with a focus on quality, accessibility, and reliable product presentation. The HPV Rapid Test Device (Urine) is designed for healthcare buyers looking for a non-invasive HPV screening support product.

Advantages

• Urine-based HPV screening support
• Colloidal gold method as per product specification
• Rapid device format
• Easy sample collection
• Suitable for women’s health and STI screening programs
• Useful for clinics, laboratories, and distributors
• International product positioning under LARKSOIS Pharma